ClinicalTrials.Veeva
Menu

Find clinical trials for Chronic Lymphocytic Leukemia in Boston, MA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Chronic Lymphocytic Leukemia
Leukemia
Lymphoid Leukemia
Lymphoma
B-Cell Lymphoma
Mantle-Cell Lymphoma
Non-Hodgkin Lymphoma

Chronic Lymphocytic Leukemia trials near Boston, MA, USA:

A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

This research study is evaluating a combination of two drugs, ibrutinib and obinutuzumab, as a possible treatment for Chronic Lymphocytic...

Active, not recruiting
Chronic Lymphocytic Leukemia
Drug: Ibrutinib
Drug: Obinutuzumab

Phase 1

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Boston, Massachusetts, United States and 3 other locations

over 12 cycles (approximately 1 year) as first-line treatment of chronic lymphocytic leukemia or small lymphocytic...

Enrolling
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Pirtobrutinib
Drug: Obinutuzumab

Phase 2

Inhye Ahn

Boston, Massachusetts, United States and 2 other locations

new drug called ibrutinib in combination with the standard drugs fludarabine, cyclophosphamide, and rituximab (FCR) as a possible treatment for Chronic...

Active, not recruiting
Chronic Lymphocytic Leukemia
Leukemia
Drug: Rituximab
Drug: Cyclophosphamide

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Boston, Massachusetts, United States and 8 other locations

A study of acalabrutinib plus venetoclax (AV) versus venetoclax plus obinutuzumab (VO) in previously untreated chronic lymphocytic ...

Active, not recruiting
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Drug: Obinutuzumab
Drug: Venetoclax

Phase 3

AstraZeneca
AstraZeneca

Boston, Massachusetts, United States and 40 other locations

The purpose of this study is to determine the rate of minimum residual disease (MRD) negative response (i.e. the rate of no evidence of disease) of t...

Enrolling
Small Lymphocytic Leukemia (SLL)
Chronic Lymphocytic Leukemia (CLL)
Drug: Venetoclax
Drug: Obinutuzumab

Phase 2

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

Boston, Massachusetts, United States and 7 other locations

Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study...

Enrolling
Chronic Lymphocytic Leukemia (CLL)
Drug: Venetoclax
Drug: Obinutuzumab

Phase 2

AbbVie
AbbVie

Boston, Massachusetts, United States of America and 48 other locations

This study is evaluating the safety and efficacy of a new BTK inhibitor, acalabrutinib, for the treatment of chronic lymphocytic le...

Active, not recruiting
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Acalabrutinib

Phase 1, Phase 2

Acerta Pharma
Acerta Pharma

Boston, Massachusetts, United States and 11 other locations

new drug called IPI-145 in combination with the standard drugs fludarabine, cyclophosphamide, and rituximab (FCR), as a possible treatment for chronic...

Active, not recruiting
Chronic Lymphocytic Leukemia
Drug: Rituximab
Drug: Cyclophosphamide

Phase 1, Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Boston, Massachusetts, United States and 1 other location

with Obinutuzumab in subjects with relapsed or refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma....

Active, not recruiting
Lymphoma, Non-Hodgkin
Drug: CC-99282
Drug: Obinutuzumab

Phase 1

Celgene
Celgene

Boston, Massachusetts, United States and 14 other locations

This research study is evaluating the combination of three drugs - acalabrutinib, venetoclax, and obinutuzumab -- as a possible treatment for chronic...

Active, not recruiting
Chronic Lymphocytic Leukemia (CLL)
Drug: Venetoclax
Drug: Acalabrutinib

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Boston, Massachusetts, United States and 3 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems